Frame Bio Collaborates with Mercury Bio to Innovate Drug Delivery
Frame Bio Collaborates with Mercury Bio to Innovate Drug Delivery
Frame Bio, a progressive biotechnology firm, has embarked on an exciting journey to develop therapeutics aimed at structural diseases and disorders. This venture is underscored by an exclusive licensing agreement with Mercury Bio, a pioneering company in drug delivery that specializes in extracellular vesicle (EV) drug encapsulation technology. This novel approach utilizes the yEV™ platform to facilitate direct transport of therapies to cells through unique exosomes, which are tiny vesicles naturally involved in cellular communication.
Understanding the yEV™ Platform
The innovative yEV™ technology by Mercury Bio acts as a sophisticated vehicle for therapeutic agents, enabling precise delivery to target cells. By incorporating specially designed targeting ligands, yEV™ enhances the effectiveness of therapeutic cargos while minimizing potential side effects. This capability could significantly improve the treatment landscape for a wide variety of conditions.
Applications in Regenerative Medicine
This partnership not only allows Frame Bio to utilize yEV™ but also provides access to Mercury Bio's extensive research and development expertise. By harnessing this technology, Frame Bio aims to create an array of regenerative therapeutics geared towards accelerating bone healing and restoring collagen. This could revolutionize how these conditions are addressed in clinical settings.
For instance, Frame Bio's therapeutic candidates will explore the incorporation of osteo-inductive proteins alongside Mercury Bio's advanced EV encapsulation methods. Hydroxyapatite, a natural form of calcium found in bones, is expected to play a vital role in enhancing the therapeutic impact at injury sites, promoting natural bone growth.
Collagen Regeneration: A Key Focus
In addition to bone health, the collaboration also emphasizes collagen regeneration. Given that collagen is the most prevalent protein within the human body and serves as a crucial component for skin and connective tissues, its loss due to aging necessitates innovative therapeutic approaches. Frame Bio's aims to reverse the biological degradation of collagen, which commonly leads to injuries and discomfort in the skin and other connective tissues.
Direct Delivery of Therapeutic Solutions
The therapies in development will first focus on direct delivery systems for mRNA payloads, targeting areas experiencing pain or injury. As both bone and collagen regeneration therapies remain in the pre-clinical phase, Frame Bio is committed to exploring various strategies to fortify its therapeutic pipeline. Collaborations with other pharmaceutical companies dedicated to biologics will be instrumental in these efforts.
About Frame Bio
Founded with initial backing from Barson Corporation, Frame Bio is at the forefront of innovative therapeutic designs that aim to tackle conditions impacting the skin-bone axis. This encompasses a holistic approach to understand the interconnectedness between skin health and bone integrity. The key focus areas for research include collagen regeneration, enhanced bone healing, and reduction of inflammation.
About Mercury Bio
Mercury Bio has become a leader in developing biomolecular drug delivery solutions that set new standards for safety and efficacy. By employing innovative targeting techniques and drug encapsulation methods, Mercury Bio's platform seeks to enhance the therapeutic effects of proteins, RNA, and small-molecule drugs. This commitment to transformative healthcare solutions aims to optimize patient outcomes by making treatments more accessible and effective.
CONTACT: Kaelie Barnard | Dir. Marketing, Barson Corp. | +1 (516) 712–6050
Frequently Asked Questions
What is the main focus of Frame Bio?
Frame Bio is focused on developing therapeutics for structural diseases, particularly targeting bone healing and collagen regeneration.
How does the yEV™ platform work?
The yEV™ platform uses exosomes to deliver therapies directly to target cells, enhancing treatment effectiveness and potentially reducing side effects.
Who is Mercury Bio?
Mercury Bio is a company specializing in advanced drug delivery technologies, particularly using extracellular vesicles for targeted therapeutics.
What collaborations are Frame Bio pursuing?
Frame Bio aims to create strategic partnerships with pharmaceutical companies to expand its product pipeline for treating connective tissue conditions.
What are BMP-2 proteins?
Bone Morphogenic Protein-2 (BMP-2) is a protein used to promote natural bone growth and is currently approved for treating certain fractures.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.